GlassScriptPhysician profile
George Dangas
NPI 1124105002
$263,035.09
in general payments reported to CMS, 2019-2025
26 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $12K · 2021: $11K · 2022: $94K · 2023: $93K · 2024: $2,480 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Travel and Lodging: $39K · Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,007.50 |
| Travel and Lodging | $38,625.77 |
| Food and Beverage | $2,032.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $215,389.15 | 2019-2025 | Savaysa, Savaysa |
| Bayer Healthcare Pharmaceuticals INC. | $23,220.00 | 2019-2020 | |
| Medtronic Vascular, INC. | $8,207.91 | 2019 | |
| Daiichi Sankyo Company LTD | $4,792.68 | 2019-2023 | Savaysa |
| Medtronic, INC. | $2,550.33 | 2021-2022 | |
| Edwards Lifesciences Corporation | $2,302.57 | 2022-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Philips North America LLC | $1,941.89 | 2019-2021 | |
| Abiomed | $1,705.74 | 2019-2025 | Impella |
| Abbott Laboratories | $1,390.10 | 2019-2025 | Navitor, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Penumbra, INC. | $338.12 | 2020-2022 | |
| Shockwave Medical, INC | $220.29 | 2021 | |
| Boston Scientific Corporation | $149.96 | 2019 | |
| Teleflex LLC | $138.58 | 2021 | |
| Cardiovascular Systems INC. | $125.00 | 2019 | |
| Scpharmaceuticals INC. | $119.85 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.30 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.62 | 2019 | |
| Amgen INC. | $80.21 | 2021-2025 | Repatha, Repatha |
| Cardiva Medical, INC. | $63.33 | 2023 | Cardiva Vascade 5f Vcs |
| Chiesi USA, INC. | $36.92 | 2019-2023 | Kengreal |
| Cook Medical LLC | $25.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.28 | 2020 | |
| Acist Medical Systems, INC. | $22.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.34 | 2023 | Camzyos |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dangas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.